Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade
Open Access
- 9 April 2021
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 62 (12) , 1751-1758
Abstract
Background: Radium-223 dichloride ([223Ra]RaCl2) is the first approved alpha particle-emitting therapy and is indicated for treatment of bone metastatic castrate resistant prostate cancer. Approximately half of the dose is absorbed into the gastrointestinal (GI) tract within minutes of administration, limiting disease-site uptake and contributing to toxicity. Here, we investigate the role of enteric ion channels and their modulation for improved therapeutic efficacy and reduced side effects. Methods: Utilizing primary human duodenal organoids (enteroids) as in vitro models of the functional GI epithelium, we found that Amiloride (ENaC blocker) and NS-1619 (K+ channel activator) presented significant effects in 223Ra membranal transport. The radioactive drug distribution was evaluated for lead combinations in vivo, and in osteosarcoma and prostate cancer models. Results: Amiloride shifted 223Ra uptake in vivo from the gut, to nearly double the uptake at sites of bone remodeling. Bone tumor growth inhibition with the combination as measured by bioluminescent and X-ray imaging was significantly greater than single agents alone, and the combination resulted in no weight loss. Conclusion: This combination of approved agents may be readily implemented as a clinical approach to improve outcomes of bone metastatic cancer patients with the benefit of ameliorated tolerability.Keywords
This publication has 34 references indexed in Scilit:
- Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Molecular Pathways: Targeted α-Particle Radiation TherapyClinical Cancer Research, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of NomenclatureJournal of Nuclear Medicine, 2009
- LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasisThe Prostate, 2000
- Selective activation of Ca2+ -dependent K+ channels by novel benzimidazoloneEuropean Journal of Pharmacology, 1994
- Distribution of Radioactive Calcium, Strontium, Barium and Radium Following Intravenous Injection into a Healthy ManInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1968
- Plasma Concentration and Excretion of Calcium-47, Strontium-85, Barium-133 and Radium-223 following Successive Intravenous Doses to a Healthy ManNature, 1966